Thymosin-beta-4 neurotrophic corneal cases
Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin beta4.
Dunn SP, Heidemann DG, Chow CY, Crockford D, Turjman N, Angel J, Allan CB, Sosne G. · Annals of the New York Academy of Sciences
Study record
- Population
Nine patients aged 37–84 with chronic nonhealing neurotrophic corneal epithelial defects: six geographic defects and three punctate defects.
Read source · Abstract-level extractionPrimary abstract — clinical report; full text unavailable- Formulation
Sterile thymosin-beta-4 eye drops. Concentration, excipients and exact preparation not available in the abstract.
Inspect extraction gap · Abstract-level extractionPrimary abstract — clinical report; full text unavailable- Route
Topical ophthalmic eye drops.
Read source · Abstract-level extractionPrimary abstract — clinical report; full text unavailable- Dose & frequency
Amount per application and dosing frequency are not specified in the abstract. No human or KLOW regimen can be derived.
Inspect extraction gap · Abstract-level extractionPrimary abstract — clinical report; full text unavailable- Study design
Compassionate-use uncontrolled cases. No randomized comparator. Possible overlap with the similarly titled ophthalmology report PMID20457990 is unverified; do not count the reports as separate cohorts.
Read source · Abstract-level extractionPrimary abstract — clinical report; full text unavailable- Duration
Treatment for 28 or 49 days, with 30-day follow-up as reported; not a repeated dosing cycle.
Read source · Abstract-level extractionPrimary abstract — clinical report; full text unavailable- Reported findings
Six patients with geographic defects showed healing without clinically significant neovascularization; three with punctate defects had no demonstrable clinical change. All reported reduced irritation. Uncontrolled observations cannot establish causality.
Read source · Abstract-level extractionPrimary abstract — clinical report; full text unavailable- Adverse events
Stromal thinning observed in one patient. No clinically significant neovascularization reported in the geographic-defect subgroup. Complete adverse-event ascertainment is not supplied.
Inspect extraction gap · Abstract-level extractionPrimary abstract — clinical report; full text unavailable- Monitoring
Clinical defect assessment and reported irritation; visit schedule, examination methods and safety-monitoring details unavailable.
Inspect extraction gap · Abstract-level extractionPrimary abstract — clinical report; full text unavailable
What it supports
Limited formulation- and indication-specific human evidence.
What it does not establish
Abstract-level report; cannot establish systemic TB-500, peptide pairing, KLOW efficacy or long-term safety. No cross-study dose substitution.
Funding
Not reported in available abstract.
Literature search cutoff: 2026-09-08 · Not independently clinically reviewed
Browse study library